Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035137 · ClinicalTrials.gov registry record · Phase 2
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
A Phase 2 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT02035137 is a Phase 2 study that has completed, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 114 participants.
The verdict
NCT02035137, a Phase 2 study, has completed, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
Interventions
- DRUG Vincristine
- DRUG Irinotecan
- DRUG Vorinostat
- RADIATION 131I-MIBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035137
The ClinicalTrials.gov registry entry for NCT02035137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vincristine is the first listed.
NCT02035137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02035137 about?
NCT02035137 is a clinical study titled "131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat". This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
What is the current status of trial NCT02035137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2014-07. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT02035137?
The interventions under investigation include: Vincristine (DRUG), Irinotecan (DRUG), Vorinostat (DRUG), 131I-MIBG (RADIATION).
Who is sponsoring clinical trial NCT02035137?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.